This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so ...

Sound more like science fiction than actual science? Then, brace yourself because there are, at least, 15 breast cancer vaccine clinical trials in various stages in the U.S., some in phase II and III.

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Seattle media misrepresent declining vaccination rates among K-12 students in Washington state. Get the facts here.

CAMBRIDGE, MA / / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

US Health Secretary Robert F. Kennedy Jr.’s vaccine policies and commentary largely appear to contradict his pledge to revamp ...

Demand for the jab through the NHS and privately in pharmacies has remained steady since the end of the pandemic ...

The latest health updates include Centene's improved profitability forecast, US-initiated healthcare data-sharing plans ...

HCA Healthcare raises 2025 profit forecast amidst insurance uncertainty while Centene anticipates a 2026 profitability boost ...

If you're confident that its current trials will prove successful, then this is one to buy and sit on. One word of caution ...

Even so, the panel agreed with the doctors that the line between government speech and private expression can get blurry.

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...